1. All Products
  2. AMOXICILLIN 500mg/ CLAV.ac. 62.5mg/5ml,powder oral susp 60ml
Public Pricelist

AMOXICILLIN 500mg/ CLAV.ac. 62.5mg/5ml,powder oral susp 60ml

https://medicalguidelines.msf.org/en/node/356
https://unicat.msf.org/cat/product/11851
NST DORAAMOC1S6

Valid Article

Former Code(s): -X
Article is intended to be used with children (<12 years) ONLY.
6.2.1 - Access group antibiotics
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
J01CR02
Anatomical Therapeutic Chemical Classification according to WHOCC
1525
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

This combination does not exist.

Add article to list

   
Create Cancel

Add Kit To Wishlist

   
Create Cancel

AMOXICILLIN/CLAVULANIC acid

Therapeutic Action

Combination of two antibacterials.

The addition of clavulanic acid to amoxicillin extends its spectrum of activity to cover beta-lactamase producing Gram-positive and Gram-negative organisms, including some Gram-negative anaerobes.

Indications

Infections due to bacteria which are resistant to amoxicillin used alone.

Continuation of parenteral treatment for severe infections (e.g. severe pneumonia).

Instructions for use

Ratio 7:1

The dispersible tablet is intended for young children and is more suitable for most MSF projects than the powder for suspension (larger volume, reconstitution, refrigeration of the reconstituted suspension, etc.).

The powder for oral suspension is only indicated for infants up to 2 months of age. To be reconstituted with filtered water.

Precautions for Use

The formulations with a ratio 8:1 (DORAAMOC1S6 and DORAAMOC56T) became NST due to supply issues. Initially, the ratio 8:1 was reserved to French-speaking countries. However, the ratio 7:1 can now be imported in French and/or English-speaking countries.

Ratios 7:1 and 8:1 are therapeutically equivalent.

Storage

  • Below 25ºC -Protect from sunlight
  • After reconstitution, keep the oral suspension refrigerated between 2ºC and 8°C for 7 days maximum.